Compare Mondaycom Ltd (MNDY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Mondaycom Ltd trades at $73.54 (market cap $3.24B), while Regeneron Pharmaceuticals Inc trades at $675 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 21.8× Mondaycom Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| MNDY | REGN | |
|---|---|---|
Market Cap | $3.24B | $70.47B |
Sector | Technology | Health |
52-Week High | $292.24 | $812.27 |
52-Week Low | $58.81 | $545.46 |
Enterprise Value | $2.21B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $76.75, down 2.47% on the day, reflecting recent bearish pressure. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 versus $0.96 expected. Revenue reached $1.23 billion in 2025 with a net income margin of 9.17%. Technical indicators signal a bearish trend, with the price near key support at $75. The company announced Q2 2026 results will be reported on August 10, 2026 (Business Wire, 2026-07-20).
The investment outlook is mixed: strong analyst consensus (76% buy ratings) and a $115.50 price target suggest significant upside, but technical weakness and a high EV/EBITDA of 97.72 pose risks. Earnings growth and AI integration present opportunities, while market volatility and competitive pressures remain concerns.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
